Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction

Journal of Cardiovascular Pharmacology
A P DrexlerR R Brooks

Abstract

The class III antiarrhythmics azimilide dihydrochloride and dl-sotalol were evaluated for ability to suppress induction of ventricular tachyarrhythmias (VT) in anesthetized, male mongrel dogs 4-6 days after surgical infarction of the left ventricle (LV) produced by ligation/reperfusion of the left anterior descending coronary artery. Postmortem infarcts averaged 28.2 +/- 3.3% and 27.5 +/- 3.9% of the LV for azimilide- and sotalol-treated dogs, respectively. Both agents (0.3-30 mg/kg i.v.) increased ventricular effective refractory period as a function of dose in LV normal and infarcted zones without increasing conduction time. Azimilide was well tolerated hemodynamically up to 30 mg/kg i.v., whereas sotalol produced a significant and dose-related decrease in both blood pressure and heart rate. Azimilide was effective in five (56%) of nine dogs in preventing induction of ventricular arrhythmias by programmed electrical stimulation (PES) at doses from 1 to 30 mg/kg. Efficacy was seen for nonsustained and sustained VT and for ventricular fibrillation. Although sotalol (0.3-10 mg/kg) was effective in all five VT dogs tested, one of two nonsustained ventricular tachyarrhythmia (NSVT) dogs and two of three sustained ventricular tachy...Continue Reading

References

Dec 1, 1979·Circulation·N K Wenger
Dec 1, 1988·Journal of the American College of Cardiology·R GonzalezH Sharkey
Apr 30, 1987·The American Journal of Cardiology·L N HorowitzS R Spielman
Dec 1, 1980·The American Journal of Cardiology·M E JosephsonA M Greenspan
Jan 1, 1993·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D Gautheret, R Cedergren
Feb 1, 1993·Journal of Cardiovascular Pharmacology·F ChézalvielG Cheymol
Jan 1, 1994·Canadian Journal of Physiology and Pharmacology·F CoceaniE Seidlitz
May 1, 1996·Proceedings of the Society for Experimental Biology and Medicine·R R BrooksA E Maynard

❮ Previous
Next ❯

Citations

Sep 7, 2001·Biochemical Pharmacology·R R BrooksD J Triggle
Aug 10, 1999·European Journal of Pharmacology·Y XueK Hashimoto
Jul 13, 2000·Journal of Chromatography. a·F J dos Ramos
Jul 1, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Junichiro MiakeIchiro Hisatome
Mar 24, 2000·Drugs·D Clemett, A Markham
Feb 2, 2000·Proceedings of the Society for Experimental Biology and Medicine·R R BrooksD R Kostreva
Apr 16, 1998·The American Journal of Cardiology·R KaramA Moore
Dec 20, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·Fuhua ChenThomas S Klitzner
Jul 14, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·S C VerduynM A Vos
Feb 10, 2000·Current Opinion in Cardiology·P T Sager
Feb 5, 1999·Current Opinion in Cardiology·P T Sager
Aug 15, 2000·Journal of Cardiovascular Pharmacology·V Nand, S A Doggrell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.